Center For AIDS Research Logo
You are here: Home About Director's biography

Director's biography

Douglas D. Richman, MD, is one of the pioneers in HIV research. His laboratory was the first to identify HIV drug resistance.

Douglas D. Richman, MD, is Distinguished Professor of Pathology and Medicine at the University of California, San Diego, and the Florence Seeley Riford Chair in AIDS Research. He is Director of the Center for AIDS Research at UC San Diego, Director of the UC San Diego AIDS Research Institute, and staff physician at the VA San Diego Healthcare System.

Background

Dr. Richman trained as an infectious disease physician and medical virologist at Stanford University, the National Institutes of Health, and Harvard University before joining the faculty at UC San Diego in 1976.

Early research

Dr. Richman's laboratory was the first to identify HIV drug resistance. The lab joined two others in identifying latently infected CD4 cells as the obstacle to eradication of HIV with potent antiretroviral therapy. His laboratory also described the dynamics of the neutralizing antibody response to HIV and the rapidity of viral escape and evolution in response to this selective pressure.

Current research

Dr. Richman's laboratory currently focuses on the natural history and molecular pathogenesis of HIV in a cohort of acutely infected patients. These studies include the cell mediated and neutralizing antibody immune responses to HIV and the viral escape and evolution in response to these. Another area of investigation includes the many virological and host determinants of HIV transmission; this knowledge central for the development of an effective HIV vaccine. Additional virologic investigations include studies of HIV drug resistance, and the pathogenetic consequences of virus replication in anatomic compartments.

The major current focus of Dr. Richman’s laboratory is the latent HIV reservoir and strategies to achieve eradication of this reservoir. Of particular interest is the development of assays to measure this reservoir in various compartments of the body and in the various subsets of CD4 lymphocytes in order to characterize the targets of intervention strategies and to measure the impact of these interventions reliably.

CFAR Highlights

From June 2006 - December 2014, CFAR Core facilities contributed to more than 640 published manuscripts and more than 185 conference abstracts.

Read More >>